Today Averica Discovery announced its acquisition by Neopharm Labs, an analytical testing lab based out of Quebec. Together the companies offer a full range of services that cover every stage of the drug development cycle including R&D, method development and validation, impurity isolation and profiling, stability testing and management, and commercial testing in chemistry and microbiology.
Excerpt from Press Release –
“Our clients can now take advantage of an expanded range of services,” adds Dr. Jeffrey Kiplinger, President and CEO of Averica Discovery, who joins Neopharm’s Executive Team as Vice President, Science & Innovation. “With this expansion into the U.S. market, Neopharm Labs builds on our combined strengths and capabilities to provide the very best services to its customers and to ours.”